文献速递血栓与止血

抑制人FcγRIII可防止FNAIT双人源化小鼠模型中的血小板破坏

Inhibition of human FcγRIII prevents platelet destruction in a dual-humanized murine model of FNAIT.
PubMed 文献 · Blood Adv · 2026-01-01

本研究探讨抗HPA-1a抗体介导血小板清除的机制,发现FcγR依赖性吞噬是主要途径,而补体固定、血小板活化和去唾液酸化仅见于少数患者。在双人源化小鼠模型中,FcγRIII阻断抗体显著减少血小板清除,提示FcγRIII阻断是FNAIT的潜在预防策略。

要点

  • 抗HPA-1a抗体通过FcγR依赖性吞噬导致血小板破坏,为FNAIT主要机制。
  • 补体固定、血小板活化和去唾液酸化仅见于少数FNAIT患者样本。
  • FcγRIII阻断单价抗体可显著减少双人源化小鼠模型中的血小板清除。

核心结论

  • FcγRIII依赖性吞噬是抗HPA-1a抗体驱动血小板清除的主要机制,FcγRIII阻断是有前景的FNAIT预防策略。

研究设计与样本

  • 体外检测FNAIT患者血浆样本中抗HPA-1a抗体诱导的血小板吞噬、补体固定、活化及去唾液酸化。
  • 构建表达HPA-1a的血小板(APLDQ转基因小鼠)与人FcγR替代鼠FcγR的双人源化小鼠模型。

主要发现

  • 混合血浆及10例FNAIT患者中9例的个体样本中,抗HPA-1a抗体在体外诱导FcγR依赖性血小板吞噬。
  • 补体固定、血小板活化(CD62P表达)和去唾液酸化(蓖麻凝集素I结合)仅见于少数患者。
  • APLDQ小鼠血小板经抗HPA-1a血清致敏后在FcγR人源化受体小鼠体内快速清除。
  • 预先给予FcγRIII阻断单价抗体显著减少血小板清除。

临床怎么用

  • FcγRIII阻断可能作为FNAIT中预防抗HPA-1a介导血小板清除的靶向策略。

局限性

  • 补体激活和血小板去唾液酸化仅见于少数样本,其对血小板破坏的贡献仍属推测。
  • 机制发现主要基于双人源化小鼠模型,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) occurs when maternal anti-fetal platelet antibodies, most frequently against human platelet antigen 1a (HPA-1a), cause fetal platelet destruction. The precise pathogenic mechanisms remain incompletely understood. Here, we examined potential mechanisms underlying anti-HPA-1a-mediated platelet clearance, focusing on phagocytosis, complement fixation, platelet activation, and desialylation. Anti-HPA-1a antibodies in pooled plasma and in individual samples of 9 of 10 patients with FNAIT induced Fc gamma receptor (FcγR)-dependent platelet phagocytosis in vitro, indicating this as the major contributor to platelet destruction. In contrast, complement fixation, platelet activation (CD62P expression), and desialylation (Ricinus communis agglutinin I binding) were observed in only a minority of patients. To model anti-HPA-1a-mediated platelet clearance in vivo, we developed a dual-humanized mouse model combining HPA-1a-expressing platelets (from APLDQ transgenic mice [C57BL/6 mice expressing A30P32L33D39Q470 on a murine GPIIIa backbone]) with mice engineered to express human FcγRs in place of murine FcγRs. Platelets from APLDQ mice sensitized with anti-HPA-1a sera underwent rapid clearance in these FcγR-humanized recipients. Pretreatment with an FcγRIII-blocking monovalent antibody significantly reduced clearance, confirming FcγRIII's central role in mediating platelet destruction. These results demonstrate that FcγRIII-dependent phagocytosis is a dominant mechanism in anti-HPA-1a-driven platelet clearance in this model. Although complement activation and platelet desialylation were observed in a minority of samples, their contribution to platelet destruction remains speculative. Together, these findings highlight the complexity of FNAIT pathophysiology yet identify FcγRIII blockade as a promising strategy to prevent platelet clearance in this disease.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tawhidi Z, Sachs UJ, Gil Gonzalez L, et al. Inhibition of human FcγRIII prevents platelet destruction in a dual-humanized murine model of FNAIT. Blood Adv. 2026. PMID: 42269082. doi:10.1182/bloodadvances.2025019475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。